Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Secukinumab> ?p ?o. }
Showing items 1 to 45 of
45
with 100 items per page.
- Secukinumab abstract "Secukinumab is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, and psoriasis. It targets member A from the cytokine family of interleukin 17.Secukinumab was developed by Novartis Pharma AG and has completed Phase II clinical trials for plaque psoriasis in 2011.It is also in a phase II clinical trial for Multiple Sclerosis as it has exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS.".
- Secukinumab atcPrefix "L04".
- Secukinumab atcSuffix "AC10".
- Secukinumab wikiPageID "33024133".
- Secukinumab wikiPageRevisionID "582750904".
- Secukinumab atcPrefix "L04".
- Secukinumab atcSuffix "AC10".
- Secukinumab c "6584".
- Secukinumab chemspiderid "NA".
- Secukinumab h "10134".
- Secukinumab hasPhotoCollection Secukinumab.
- Secukinumab legalStatus "Investigational".
- Secukinumab mabType "mab".
- Secukinumab molecularWeight "147.94".
- Secukinumab n "1754".
- Secukinumab o "2042".
- Secukinumab s "44".
- Secukinumab source "u".
- Secukinumab synonyms "AIN457".
- Secukinumab target IL17A.
- Secukinumab type "mab".
- Secukinumab verifiedrevid "464388281".
- Secukinumab subject Category:Immunosuppressants.
- Secukinumab subject Category:Novartis.
- Secukinumab type Agent114778436.
- Secukinumab type CausalAgent100007347.
- Secukinumab type Drug103247620.
- Secukinumab type Immunosuppressant103562958.
- Secukinumab type Immunosuppressants.
- Secukinumab type Matter100020827.
- Secukinumab type Medicine103740161.
- Secukinumab type PhysicalEntity100001930.
- Secukinumab type Substance100020090.
- Secukinumab type Drug.
- Secukinumab type FunctionalSubstance.
- Secukinumab comment "Secukinumab is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, and psoriasis. It targets member A from the cytokine family of interleukin 17.Secukinumab was developed by Novartis Pharma AG and has completed Phase II clinical trials for plaque psoriasis in 2011.It is also in a phase II clinical trial for Multiple Sclerosis as it has exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS.".
- Secukinumab label "Secukinumab".
- Secukinumab label "Secukinumab".
- Secukinumab sameAs Secukinumab.
- Secukinumab sameAs m.0h560sz.
- Secukinumab sameAs Q7444755.
- Secukinumab sameAs Q7444755.
- Secukinumab sameAs Secukinumab.
- Secukinumab wasDerivedFrom Secukinumab?oldid=582750904.
- Secukinumab isPrimaryTopicOf Secukinumab.